Literature DB >> 6430252

Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.

A P Wilson, P J Prouse, J M Gumpel.   

Abstract

A 63-year-old woman with seropositive rheumatoid arthritis was successfully treated with auranofin for 12 months. Heavy proteinuria then developed and the drug was stopped. However, the proteinuria apparently became worse. This was later recognised to be a spurious effect due to the introduction of tolmetin. Renal biopsy showed a type I membranous glomerulonephropathy.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6430252      PMCID： PMC1001382          DOI： 10.1136/ard.43.3.511

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  4 in total

1.  Pseudoproteinuria in tolmetin-treated patients.

Authors:  G E Ehrlich; G F Wortham
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

2.  Reversible proteinuria as a complication of oral gold therapy.

Authors:  M Revach; R L Freed; G E Ehrlich
Journal:  Arthritis Rheum       Date:  1979-12

3.  Membranous glomerulonephritis as a complication of oral gold therapy.

Authors:  J J Plaza; G Herrero; A Barat; J J Loutaif; L Hernando; P Vallado; H Oliva
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

4.  HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  P H Wooley; J Griffin; G S Panayi; J R Batchelor; K I Welsh; T J Gibson
Journal:  N Engl J Med       Date:  1980-08-07       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.